Fennec Pharmaceuticals Inc. Share Price & Technical Analysis
FENC · $9.93 (-0.40%)
Healthcare / Biotechnology
$9.93
-0.40%
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has col…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
52% return in May, 0% avg return in past 3 year May month.
43% return in 2026, 9% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 13% | -26% | 5% | 52% | – | – | – | – | – | – | – | 43% |
| 25 | 2% | 9% | -14% | 0% | 33% | 2% | -1% | 10% | 6% | -12% | 0% | -6% | 28% |
| 24 | -10% | -6% | 17% | -17% | -26% | -10% | 7% | -14% | -9% | -10% | 39% | 5% | -35% |
| 23 | 2% | -10% | -7% | 0% | -7% | 19% | 1% | -7% | -7% | -8% | 26% | 32% | 34% |
| 22 | 7% | 19% | -2% | 5% | -2% | -2% | 18% | 6% | 16% | 9% | 10% | -1% | 83% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$243.68M
P/E ratio
—
52W high
$10.45
52W low
$5.65
Volume
1,91,294
Beta
0.91
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Fennec Pharmaceuticals Inc. share price today?
- Fennec Pharmaceuticals Inc. (FENC) last traded around $9.93 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FENC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FENC. Download the app for real-time alerts.
- How can I analyze Fennec Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.